(2022)
Parents' and childcare workers' perspectives toward SARS-CoV-2 test and surveillance protocols in pre-school children day care centers: A qualitative study within the German Wü-KiTa-CoV project.
Front Med (Lausanne) 9,
897726.
Oliver Kurzai
National Reference Center for Invasive Fungal Infections · Head Fungal Septomics · Head +49 3641 532-1347 oliver.kurzai@leibniz-hki.deCurriculum vitae
Main Research Areas
- Infection biology of human pathogenic fungi (especially Candida albicans)
- Infection biology of Neisseria meningitidis
Professional Career
Since 2017 | Chair of Medical Microbiology and Mycology, Institute for Hygiene and Microbiology, Julius Maximilians University Würzburg and head of the research group Fungal Septomics at Leibniz Institute for Natural Product Research and Infection Biology – Hans-Knöll-Institute Jena |
2009-2016 | Professor (W2) for Fungal Septomics, Friedrich-Schiller-University Jena |
2008 | Habilitation in medical microbiology, University Würzburg |
2006 | Medical specialist in microbiology, virology and infection epidemiology (Bayerische Landesärztekammer) |
2003 | Head of a working group, Institut für Hygiene und Mikrobiologie, University Würzburg |
2001-2002 | Doctor in practical training (AiP), Institut für Hygiene und Mikrobiologie, University Würzburg |
2002 | Dr. med., “summa cum laude” University Würzburg |
2001 | Staatsexamen (state examination) in human medicine, University Würzburg |
Awards · Appointments · Scientific Activities
Since 2014 | Head of the Nationales Referenzzentrums für invasive Pilzinfektionen (NRZMyk) |
Since 2013 | Board member of the Integriertes Forschungs- und Behandlungszentrum “Center for Sepsis Control and Care” (CSCC) at the University Hospital Jena |
Since 2012 | Scientific Manager of the consortium “InfectControl 2020 – New Antiinfection Strategies – Science • Society • Economy” within the BMBF-Programme “Zwanzig 20 – Partnership for Innovation” (Head: Prof. A. Brakhage) |
Since 2012 | Editor-in-chief, Medical Mycology Case Reports, member (ex officio) of the executive board of the International Society for Human & Animal Mycology (ISHAM) |
Since 2011 | Elected note taker at the Deutschsprachige Mykologische Gesellschaft DMykG |
2015-2016 | Speaker of the ZIK Septomics |
2011-2013 | Editor, Journal of Basic Microbiology |
2009 | Hans-Rieth-poster prize from the Deutschsprachige Mykologische Gesellschaft (DMykG) |
2008 | Award from the Deutsche Gesellschaft für Hygiene und Mikrobiologie |
2003 | Science award from the Unterfränkische Gedenkjahrstiftung |
2003 | Dissertation award from the medical faculty of the University Würzburg |
2002 | Becton-Dickinson PhD award from the Deutsche Gesellschaft für Hygiene und Mikrobiologie |
Publications
(2022)
Corrigendum: Parents' and childcare workers' perspectives toward SARS-CoV-2 test and surveillance protocols in pre-school children day care centers: A qualitative study within the german Wü-KiTa-CoV project.
Front Med (Lausanne) 9,
973518.
(2022)
Successful control of Candida auris transmission in a German COVID-19 intensive care unit.
Mycoses 65(6),
643-649.
(2022)
Aspergillus tracheobronchitis in COVID-19 ARDS patients - a cohort study.
Eur Respir J 59(5),
2103142.
(2022)
Increasing number of cases and outbreaks caused by Candida auris in the EU/EEA, 2020 to 2021.
Euro Surveill 27(46),
2200846.
(2022)
Bloodstream infections caused by Magnusiomyces capitatus and Magnusiomyces clavatus: epidemiological, clinical and microbiological features of two emerging yeast species.
Antimicrob Agents Chemother 66(2),
e0183421.
(2022)
Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.
J Antimicrob Chemother 77(8),
2053-2073.
(Review)
(2022)
Diagnostic accuracy and feasibility of a rapid SARS-CoV-2 antigen test in general practice - a prospective multicenter validation and implementation study.
BMC Prim Care 23(1),
149.
(2022)
Results from a national survey on COVID-19-associated mucormycosis in Germany: 13 patients from six tertiary hospitals.
Mycoses 65(1),
103-109.
(2022)
CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models.
Sci Transl Med 14(664),
eabh1209.